JP2004503471A5 - - Google Patents

Download PDF

Info

Publication number
JP2004503471A5
JP2004503471A5 JP2001585800A JP2001585800A JP2004503471A5 JP 2004503471 A5 JP2004503471 A5 JP 2004503471A5 JP 2001585800 A JP2001585800 A JP 2001585800A JP 2001585800 A JP2001585800 A JP 2001585800A JP 2004503471 A5 JP2004503471 A5 JP 2004503471A5
Authority
JP
Japan
Prior art keywords
selectin
pharmaceutical composition
stroke
animals
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001585800A
Other languages
English (en)
Other versions
JP2004503471A (ja
JP4986361B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/016583 external-priority patent/WO2001089557A2/en
Publication of JP2004503471A publication Critical patent/JP2004503471A/ja
Publication of JP2004503471A5 publication Critical patent/JP2004503471A5/ja
Application granted granted Critical
Publication of JP4986361B2 publication Critical patent/JP4986361B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 活性のある薬学的物質としての、E-セレクチン。
【請求項２】 有効量の、請求項1記載のE-セレクチンを含む、薬学的組成物。
【請求項３】 動物に寛容を誘導するために使用される、請求項1記載のE-セレクチン。
【請求項４】 バイスタンダー作用寛容がE-セレクチン投与により誘導される、請求項1記載のE-セレクチン。
【請求項５】 動物において脳卒中を治療するために使用される、請求項1記載のE-セレクチン。
【請求項６】 動物において脳卒中を予防するために使用される、請求項1記載のE-セレクチン。
【請求項７】 脳卒中後の脳損傷を軽減するために使用される、請求項1記載のE-セレクチン。
【請求項８】 高血圧、糖尿病、または高コレステロール血症を患う患者を治療するために使用される、請求項1記載のE-セレクチン。
【請求項９】 動物において脳卒中を治療する医薬を製造するための、E-セレクチンの使用。
【請求項１０】 動物において脳卒中を予防する医薬を製造するための、E-セレクチンの使用。
【請求項１１】 E-セレクチンが脳卒中後の脳損傷を軽減するために使用される、請求項9または10記載の使用。
【請求項１２】 高血圧、糖尿病、または高コレステロール血症を患う患者を治療する医薬を製造するための、E-セレクチンの使用。
【請求項１３】 動物において寛容を誘導する医薬を製造するための、請求項9〜12のいずれか一項記載のE-セレクチンの使用。
【請求項１４】 バイスタンダー作用寛容がE-セレクチン投与により誘導される、請求項9〜13のいずれか一項記載のE-セレクチンの使用。
【請求項１５】 E-セレクチンがヒトE-セレクチンである、請求項1〜14のいずれか一項記載のE-セレクチン、薬学的組成物、または使用。
【請求項１６】 E-セレクチンが鼻腔内投与される、請求項1〜14のいずれか一項記載のE-セレクチン、薬学的組成物、または使用。
【請求項１７】 E-セレクチンが2週間にわたって初回鼻腔内投される、請求項16記載のE-セレクチン、薬学的組成物、または使用。
【請求項１８】 E-セレクチンのブースター投与が初回鼻腔内投与の後に行われる、請求項16または17記載のE-セレクチン、薬学的組成物、または使用。
【請求項１９】 E-セレクチンレクチン、EGF、CR1、およびCR2ドメインを含む、請求項1記載のE-セレクチン。
【請求項２０】 E-セレクチンがE-セレクチンレクチン、EGF、CR1、およびCR2ドメインを含む、請求項2記載の薬学的組成物。
JP2001585800A 2000-05-24 2001-05-23 Ｅ−セレクチンに対する寛容誘導による脳卒中防止法 Expired - Fee Related JP4986361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20669300P 2000-05-24 2000-05-24
US60/206,693 2000-05-24
PCT/US2001/016583 WO2001089557A2 (en) 2000-05-24 2001-05-23 Methods for preventing strokes by inducing tolerance to e-selectin

Publications (3)

Publication Number Publication Date
JP2004503471A JP2004503471A (ja) 2004-02-05
JP2004503471A5 true JP2004503471A5 (ja) 2008-06-26
JP4986361B2 JP4986361B2 (ja) 2012-07-25

Family

ID=22767527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585800A Expired - Fee Related JP4986361B2 (ja) 2000-05-24 2001-05-23 Ｅ−セレクチンに対する寛容誘導による脳卒中防止法

Country Status (11)

Country Link
US (2) US7261896B2 (ja)
EP (2) EP2295067A1 (ja)
JP (1) JP4986361B2 (ja)
AT (1) ATE367823T1 (ja)
AU (2) AU2001264813B2 (ja)
CA (1) CA2410563C (ja)
DE (1) DE60129552T2 (ja)
DK (1) DK1286686T3 (ja)
ES (1) ES2292594T3 (ja)
PT (1) PT1286686E (ja)
WO (1) WO2001089557A2 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292594T3 (es) * 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
WO2007028133A2 (en) * 2005-08-30 2007-03-08 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment and prevention of vascular dementia
US20070244043A1 (en) * 2005-03-10 2007-10-18 Novavax, Inc. Recombinant E-selectin made in insect cells
US7939078B2 (en) * 2005-07-07 2011-05-10 Codman & Shurtleff Methods of enhancing the immune response to autoantigens in mucosal associated lymphatic tissue
EP2081584A2 (en) * 2006-10-09 2009-07-29 Government Of The United States Of America As Represented by Secretary of the Dep. of Health and Human Services National Institute of Health Treatment of inflammation, demyelination and neuronal/axonal loss
WO2009038880A1 (en) * 2007-08-01 2009-03-26 Novavax, Inc. Novel e-selectin variant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
BR9007527A (pt) 1989-07-14 1992-06-23 Autoimmune Inc Metodo para tratar ou prevenir a manifestacao clinica de uma doenca tendo os sintomas de uveoretinite e formulacao farmaceutica para tratar mamiferos sofrendo de uveoretinite
AU642693B2 (en) 1989-12-20 1993-10-28 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
BR9106114A (pt) 1990-03-02 1993-03-09 Autoimmune Inc Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
IL165071A (en) 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IL99754A (en) 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
JP3712260B2 (ja) 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
EP0863155B1 (en) 1992-04-09 2002-01-23 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
AU5080393A (en) 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
CA2185353A1 (en) 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
EP0752879A4 (en) 1994-04-08 1999-07-21 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES WITH TOLERANCE INDUCING AGENTS AND / OR ORAL TH2-ENHANCING CYTOKINES
US5891645A (en) * 1994-06-01 1999-04-06 Alexion Pharmaceuticals, Inc. Porcine E-selectin
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US20010056073A1 (en) * 1998-07-21 2001-12-27 Ascher Shmulewitz Gene therapy method for revascularizing ischemic tissue
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US7897575B2 (en) * 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
ES2292594T3 (es) * 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.

Similar Documents

Publication Publication Date Title
BRPI0206432A2 (pt) métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
JP2006501240A5 (ja)
AR020050A1 (es) COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA ENFERMEDAD AMILOIDOGENICA USO DE UN PÉPTIDO ABETA PARA LA PREPARACIoN DE MEDICAMENTOS
JP2002532432A5 (ja)
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
UA83320C2 (ru) Таблетка для рассасывания, содержащая октенидин и предназначенная для лечения воспалительных заболеваний полости рта и глотки
ATE251901T1 (de) Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
JP2004537500A5 (ja)
EP1677806A4 (en) METHOD FOR THE TREATMENT OF ACUTE AND HYALURONIC ACIDIFICATION CAUSED BY EXCESSIVE INJURY AND STUPIDATION
JP2004503471A5 (ja)
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
DE60119976D1 (en) Thixotropes nasenspray
JP2003528919A5 (ja)
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
BR0104586A (pt) Método para tratamento de neurodegeneração
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)